

Disclosure of movement of 1% or more in substantial holding  
or change in nature of relevant interest, or both

*Sections 277 and 278, Financial Markets Conduct Act 2013*

**To** NZX Limited (**NZX**)

and

**To** Rua Bioscience Limited (**Rua**)

Relevant event being disclosed: Movement of 1% or more in the substantial holding

Date of relevant event: 4 June 2021

Date this disclosure made: 8 June 2021

Date last disclosure made: 22 October 2020

**Substantial product holder(s) giving disclosure**

Full name(s): Hikurangi Bioactives Limited Partnership (**HBLP**) and Hikurangi Bioactives GP Limited (**HGPL**)

**Summary of substantial holding**

Class of quoted voting products: ordinary shares in Rua

Summary for HBLP and HGPL

For **this** disclosure,—

(a) total number held in class: 17,616,591

(b) total in class: 140,262,591

(c) total percentage held in class: 12.58%

For **last** disclosure,—

(a) total number held in class: 23,488,787

(b) total in class: 140,012,225

(c) total percentage held in class: 16.776%

**Details of transactions and events giving rise to relevant event**

Details of the transactions or other events requiring disclosure:

- The dates of the beginning and end of the period of the aggregated on market and off market trades are 19 March 2021 and 4 June 2021.
- The nature of the transactions is on-market and off-market sale of the shares.
- The total consideration received for aggregated on-market trades is NZ\$568,740.80 (before fees) for 1,380,000 ordinary shares in Rua.

- The total consideration received for aggregated off-market trades is NZ\$1,662,112.00 (before fees) for 4,492,196 ordinary shares in Rua.
- The total number of ordinary shares in Rua to which the aggregated on-market and off-market trades related is 5,872,196.

**Details after relevant event**

Details for HBLP

Nature of relevant interest(s): Registered holder and beneficial owner of the shares

For that relevant interest,—

- (a) number held in class: 17,616,591
- (b) percentage held in class: 12.58%
- (c) current registered holder(s): HBLP
- (d) registered holder(s) once transfers are registered: unknown

For a derivative relevant interest, also—

- (a) type of derivative: Not applicable
- (b) details of derivative: Not applicable
- (c) parties to the derivative: Not applicable
- (d) if the substantial product holder is not a party to the derivative, the nature of the relevant interest in the derivative: Not applicable

Details for HBGPL

Nature of relevant interest(s): HBGPL has the responsibility, authority and power for the management and control of the business and affairs of HBLP as its general partner, and accordingly has a relevant interest in HBLP’s shares in Rua.

For that relevant interest,—

- (a) number held in class: 17,616,591
- (b) percentage held in class: 12.58%
- (c) current registered holder(s): HBLP
- (d) registered holder(s) once transfers are registered: unknown

For a derivative relevant interest, also—

- (a) type of derivative: Not applicable
- (b) details of derivative: Not applicable

- (c) parties to the derivative: Not applicable
- (d) if the substantial product holder is not a party to the derivative, the nature of the relevant interest in the derivative: Not applicable

**Additional information**

Address(es) of substantial product holder(s):

- HBLP: 6434 Waiapu Road, Rd 1, Ruatoria, 4081, New Zealand
- HBGPL: c/o Coates Associates Limited, 300 Childers Road, Gisborne, Gisborne, 4010, New Zealand

Contact details: **Damian Skinner**, [damian@hikurangibioactives.co.nz](mailto:damian@hikurangibioactives.co.nz), **Tel. 021526870**

Nature of connection between substantial product holders: HBLP and HBGPL are associated persons under section 12(1) of the Financial Markets Conduct Act 2013.

Name of any other person believed to have given, or believed to be required to give, a disclosure under the Financial Markets Conduct Act 2013 in relation to the financial products to which this disclosure relates: Manu Caddie

**Certification**

I, **Damian Hugh Skinner**, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.